Application of a subcellular membrane-antibody binding assay for the analysis of antigen expression in human tumours

Area of Science:

• Immunology
• Biochemistry
• Oncology

Background:

• Monoclonal antibodies (mAbs) are crucial for cancer diagnostics and therapeutics.
• Characterizing mAb binding to specific tissue antigens is essential for their clinical application.
• Existing methods for evaluating mAb-antigen interactions can be subjective or lack sensitivity.

Purpose of the Study:

• To develop and validate a micro-radioisotopic antiglobulin assay for quantifying mAb binding to subcellular membranes.
• To assess the reactivity of a panel of mAbs against diverse tissue membrane preparations.
• To enable objective evaluation of antigen expression in clinical samples.

Main Methods:

• Utilized Terasaki Microtest Plates for adsorbing subcellular membrane preparations.
• Employed a micro-radioisotopic antiglobulin assay to detect and quantify mAb binding.
• Tested 15 distinct monoclonal antibodies against 22 membrane preparations from normal and malignant colorectal, breast, and lung tissues.

Main Results:

• The assay demonstrated objective and reproducible measurement of antibody binding.
• Successfully identified and quantified the reactivity of monoclonal antibodies against specific membrane antigens.
• Enabled the definition of major antigen expression profiles in individual surgical specimens.

Conclusions:

• The micro-radioisotopic antiglobulin assay is a sensitive and objective tool for evaluating monoclonal antibody reactivity.
• This assay facilitates the characterization of antigen expression in cancer tissues, aiding in biomarker discovery and therapeutic development.
• The method holds promise for improving the diagnostic and prognostic accuracy of cancer-related biomarkers.